Acute and Preventive Therapy for Migraine

Experts in the management of migraine discuss the prevalence of individuals taking acute migraine therapy and enumerate the various classes of agents available.

Key opinion leaders briefly discuss unmet needs in the acute migraine space and how to determine when to switch from an acute agent.

Migraine specialists consider the drivers of health care utilization for uncontrolled migraine and discuss where individuals go to seek help for management.

A discussion on how advancements in migraine understanding have improved diagnostics and treatment.

Key opinion leaders discuss the process of determining and measuring individualized treatment goals to ensure patients with migraine receive the most effective management.

Experts in the management of migraine consider the factors that contribute to transitioning a patient from acute to preventive care.

A retrospective analysis of preventive care and how advancements have allowed for more effective management of migraine.

A discussion on emerging CGRP monoclonal antibodies for the prevention of migraine onset.

Key opinion leaders discuss the various adverse events of emerging CGRP monoclonal antibody treatments and compare efficacy data.

A migraine expert discusses clinical trial data on 2 CGRP monoclonal antibodies regarding adverse events and safety primary end points.

Key opinion leaders discuss the process of selecting the right therapy for patients with migraine, with special consideration of the importance of patient preference, and how long to stick with a therapy.

A discussion on how to accurately measure response to goal-based therapy and ensure patients are receiving appropriately effective treatment.

Migraine experts consider how to safely and effectively combine acute and preventive therapy to meet individualistic and complex management needs.

A discussion on how the coronavirus pandemic has affected conventional management of patients with migraine, and how to circumnavigate shortcomings.